Sienna Biopharmaceuticals, Inc.
SNNA
SNNA was delisted on the 16th of December, 2019.
57 hedge funds and large institutions have $36.4M invested in Sienna Biopharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 11 closing their positions.
118% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 11
69% more capital invested
Capital invested by funds: $21.6M → $36.4M (+$14.8M)
5% less funds holding
Funds holding: 60 → 57 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.57M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$3M |
| 3 |
LM
Luminus Management
Houston,
Texas
|
+$2.57M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.17M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$2.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$316K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$232K |
| 3 |
SG Americas Securities
New York
|
-$78K |
| 4 |
JP Morgan Chase
New York
|
-$41K |
| 5 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$40K |
SNNA Hedge Fund Activity: Q1 2019 in Review
57 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Sienna Biopharmaceuticals, Inc. (SNNA) for Q1 2019, worth a combined $36.4M — up 69% from $21.6M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SNNA and 8 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 24 added.
The largest buyer was Fidelity Investments, adding an estimated $3.57M. The largest seller was Clough Capital Partners, exiting entirely with an estimated $316K sold.
- 57 institutional investors held Sienna Biopharmaceuticals, Inc. (SNNA) as of Q1 2019, down from 60 in Q4 2018.
- Funds reported $36.4M of Sienna Biopharmaceuticals, Inc. stock for Q1 2019, up 69% quarter-over-quarter.
- 8 funds opened new Sienna Biopharmaceuticals, Inc. positions in Q1 2019 and 11 closed out, a net change of -3 holders.
- The largest Sienna Biopharmaceuticals, Inc. buyer in Q1 2019 was Fidelity Investments, an estimated $3.57M added.
- The largest Sienna Biopharmaceuticals, Inc. seller in Q1 2019 was Clough Capital Partners, an estimated $316K sold.
Based on aggregated 13F filings for Q1 2019.